• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis Limited appoints distributor for key North America region
Share
Announcements, Neutrophil Elastase Immunoassay, News

ProAxsis Limited appoints distributor for key North America region

November 19, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Diapharma Group Inc. as the exclusive distributor of its portfolio of respiratory research assays for the North America region.

Based in Ohio, Diapharma has specialised in the commercialisation of products within the research and diagnostic fields in the United States and Canada since it was founded in 1997. This partnership agreement provides them with exclusive access to ProAxsis’ activity-based immunoassay kits for the quantification of the active forms of neutrophil elastase, proteinase 3 and cathepsin G.

Speaking about the agreement, Dr David Ribeiro, CEO of ProAxsis, said: “We’re delighted to have reached this agreement with Diapharma.  Finding a suitable commercial partner for our portfolio in North America was a key short-term objective for the company and we are very excited about partnering with a company that has such experience in the commercialisation of research-focused products in this region of substantial commercialisation potential.”

With over 20 years of expertise in proteolytic enzyme activity assays, DiaPharma sees a natural fit with ProAxsis. Olivia Stricker, PhD, Business Development Manager at Diapharma, added: “We’re pleased to have gained access to the innovative ProteaseTag® technology of ProAxsis and look forward to providing our customers with solutions for protease-focused research at the bench and clinical trials.”

Any enquiries concerning ProAxsis’ work with proteases and other inflammatory biomarkers can be directed to info@proaxsis.com. 

To learn more about Diapharma, please visit www.diapharma.com.

ABOUT PROAXSIS

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has developed activity-based immunoassays for the specific quantification of the active form of Neutrophil Elastase, Proteinase 3 and Cathepsin G.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.

Aside from the provision of assays, ProAxsis is able to offer a sample analysis service at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis became a fully owned subsidiary of Netscientific plc in October 2020. 

ABOUT DIAPHARMA

DiaPharma Group, Inc. in West Chester, Ohio is a privately held distributor of superior biotechnology products throughout the US and Canada.  For over 25 years, DiaPharma has been the exclusive distributor of Chromogenix, a gold standard in chromogenic substrate technology,  and have grown to represent assays for hemostasis and thrombosis, as well as unique biomarkers for organ damage, oncology, autoimmunity, infectious diseases, metabolic syndrome, and ecotoxicology.  The product menu ranges from chromogenic substrates, activity assays, ELISA kits and antibodies to instrumentation.   Diapharma’s team provides strong technical competence and experience to clinical and research scientists to ensure customer expectations will be met or exceeded.

November 19, 2020

Related News

Other posts that you should not miss.
Announcements, News

NetScientific acquires 100% control of portfolio company ProAxsis Limited

October 16, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, …

Read More
October 16, 2020
Posted by David Ribeiro
Conferences, Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016

December 8, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay …

Read More
December 8, 2016
Posted by Webmaster
Announcements, News

Dr Kelly Moffitt joins ProAxsis team

May 9, 2016
-
Posted by Webmaster

ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior …

Read More
May 9, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
NEXT POST →
NetScientific acquires 100% control of portfolio company ProAxsis Limited
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • February 21, 2021
    ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
124 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
124 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
145 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
165 days ago
- ProAxsis
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis Limited appoints distributor for key North America region | ProAxsis